Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.

Dupuis-Girod S, Rivière S, Lavigne C, Fargeton AE, Gilbert-Dussardier B, Grobost V, Leguy-Seguin V, Maillard H, Mohamed S, Decullier E, Roux A, Bernard L, Saurin JC, Saroul N, Faure F, Cartier C, Altwegg R, Laccourreye L, Oberti F, Beaudoin M, Dhelens C, Desvignes C, Azzopardi N, Paintaud G, Hermann R, Chinet T

Open source

DOI: 10.1111/joim.13714
Published: 2023 Dec
Container: Journal of internal medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/joim.13714,
  title = {Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.},
  author = {Dupuis-Girod S and Rivière S and Lavigne C and Fargeton AE and Gilbert-Dussardier B and Grobost V and Leguy-Seguin V and Maillard H and Mohamed S and Decullier E and Roux A and Bernard L and Saurin JC and Saroul N and Faure F and Cartier C and Altwegg R and Laccourreye L and Oberti F and Beaudoin M and Dhelens C and Desvignes C and Azzopardi N and Paintaud G and Hermann R and Chinet T},
  year = {2023},
  journal = {Journal of internal medicine},
  doi = {10.1111/joim.13714},
  url = {https://doi.org/10.1111/joim.13714}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.
AU  - Dupuis-Girod S
AU  - Rivière S
AU  - Lavigne C
AU  - Fargeton AE
AU  - Gilbert-Dussardier B
AU  - Grobost V
AU  - Leguy-Seguin V
AU  - Maillard H
AU  - Mohamed S
AU  - Decullier E
AU  - Roux A
AU  - Bernard L
AU  - Saurin JC
AU  - Saroul N
AU  - Faure F
AU  - Cartier C
AU  - Altwegg R
AU  - Laccourreye L
AU  - Oberti F
AU  - Beaudoin M
AU  - Dhelens C
AU  - Desvignes C
AU  - Azzopardi N
AU  - Paintaud G
AU  - Hermann R
AU  - Chinet T
PY  - 2023
JO  - Journal of internal medicine
DO  - 10.1111/joim.13714
UR  - https://doi.org/10.1111/joim.13714
ER  -

APA

S, D., S, R., C, L., AE, F., B, G., V, G., V, L., H, M., S, M., E, D., A, R., L, B., JC, S., N, S., F, F., C, C., R, A., L, L., F, O., M, B., C, D., C, D., N, A., G, P., R, H., & T, C. (2023). Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.. Journal of internal medicine. https://doi.org/10.1111/joim.13714

Source records

pubmed · retrieved 2026-09-27T01:57:00.105Z